AUAUniversity
361 episodes - English - Latest episode: 4 days ago - ★★★★★ - 32 ratingsThe AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
DEI in Urology: Surgical Implications For LGBTQ Patients
July 01, 2022 05:30 - 37 minutes - 34.2 MBCME Available: https://auau.auanet.org/node/35725 Moderator: Jay D. Raman, MD, FACS Co-Hosts: Channa Amarasekera, MD; Simon Rosser, PhD, MPH LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify two specific surgical side effects that may be of interest to a patient who undergoes a prostatectomy (e.g. ED treatment efficacy for anal penetration, climacturia, anejaculation). 2. Ask relevant questions about sexual practices that may impact the side e...
Surgical Implications For LGBTQ Patients
July 01, 2022 05:30 - 37 minutes - 34.2 MBCME Available: https://auau.auanet.org/node/35725 Moderator: Jay D. Raman, MD, FACS Co-Hosts: Channa Amarasekera, MD; Simon Rosser, PhD, MPH LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify two specific surgical side effects that may be of interest to a patient who undergoes a prostatectomy (e.g. ED treatment efficacy for anal penetration, climacturia, anejaculation). 2. Ask relevant questions about sexual practices that may impact the side e...
AUA2022: Surgical & Medical Management of High-Risk Renal Cell Carcinoma
June 29, 2022 05:30 - 1 hour - 100 MBSurgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment(2022) CME Available: https://auau.auanet.org/node/36065 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Discuss new FDA approved checkpoint inhibitors for treatment and counseling of advanced renal cell carcinoma. 2. Identify indications, risks and benefit of neoadjuvant tyrosine kinase inhibitors for downsizing renal cell carcinoma. 3. Identify appropriate tre...
AUA2022: Contemporary Pharmacotherapy for OAB 2022
June 22, 2022 05:30 - 1 hour - 109 MBContemporary Pharmacotherapy for OAB 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2022) CME Available: https://auau.auanet.org/node/36028 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB. 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combinat...
Controversies, Confusion, and the Future of Urologic Post-Operative Opioid Prescribing Strategies
June 20, 2022 05:30 - 53 minutes - 48.7 MBControversies, Confusion, and the Future of Urologic Post-Operative Opioid Prescribing Reduction Strategies CME Available: https://auau.auanet.org/node/35160 Course Director: Jennifer Robles, MD, MPH Faculty: Chad Brummett, MD; Gregory Auffenberg, MD, MS; Hitya Abraham, MD; Kevan Sternberg, MD After participating in this activity, learners will be able to: 1. Identify at least one non-pharmaceutical method they can practically implement to manage post-operative pain and reduce post-operat...
AUA2022: Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach
June 15, 2022 05:30 - 1 hour - 105 MBDifficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach (2022) CME Available: https://auau.auanet.org/node/36020 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Identify low, intermediate and high risk non-muscle invasive bladder cancer (NMIBC) 2. Recommend treatment for NMIBC based on risk stratification. 3. Identify bacillus Calmette-Guérin (BCG) unresponsive NMIBC and novel immune-based strategies and intravesical therapies. 4. Manag...
AUA2022 : The Changing Face of Advanced Prostate Cancer 2022
June 08, 2022 05:30 - 1 hour - 94.8 MBThe Changing Face of Advanced Prostate Cancer 2022(2022) CME Available: https://auau.auanet.org/node/36010 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Identify and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be able to offer additional therapies that extend survival. 2. Recognize high volume new M1 prostate cancer to be able to refer to a genitourinary (GU) medical oncologist for systemic chemo...
Update Series: AUA/ASRM Infertility Guideline Critique
June 01, 2022 05:30 - 35 minutes - 32.5 MBHost: Jay D. Raman, MD, FACS Guest: Akanksha Mehta, MD, MS For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University
AUA/ASRM Infertility Guideline Critique
June 01, 2022 05:30 - 32.5 MBHost: Jay D. Raman, MD, FACS Guest: Akanksha Mehta, MD, MS For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University
AUA2022: Diversity Equity and Inclusion in Urology: What Do We Need to Know?
May 30, 2022 05:30 - 1 hour - 104 MBDiversity Equity and Inclusion in Urology: What Do We Need to Know? CME Available: https://auau.auanet.org/node/35746 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify the different forms of racism and, more importantly, identify their own subconscious personal bias. 2. Identify the impact of race on medical education, research and clinical care. 3. Identify how DEI initiatives can positively impact the practice of urology. 4. Examine innovati...
AUA2022: Should I Order a PET Scan?
May 25, 2022 05:30 - 1 hour - 85.3 MBShould I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities CME Available: https://auau.auanet.org/node/36003 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney and urothelial cancer detection, staging and follow-up. 2. Determine the benefits of combined functional and anatomi...
Live from AUA2022: Highlights in BPH
May 18, 2022 12:26 - 1 hour - 57.3 MBCME Available: https://auau.auanet.org/node/35793 Course Director: Amy Krambeck, MD Faculty: Dean Elterman, MD; Steven Kaplan, MD; Lori Lerner, MD ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Cook Medical Olympus Corporation of the Americas LEARNING OBJECTIVES At the conclusion of the activity, participants will be able to: 1. Identify the role of diagnostic testing in making the accurate diagnosis of mLUTS using the new benign BPH guideli...
Live from AUA2022: Highlights in Advanced Prostate Cancer
May 16, 2022 17:10 - 59 minutes - 54.7 MBCME Available: https://auau.auanet.org/node/35710 Course Director: Stephen A. Boorjian, MD Faculty: Leonard G. Gomella, MD, FACS; David F. Jarrard, MD; Alicia K. Morgans, MD, MPH ACKNOWLEDGMENTS: This educational activity is supported by independent education grants from: Astellas AstraZeneca Merck & Co., Inc. Pfizer, Inc. At the conclusion of the activity, participants will be able to: LEARNING OBJECTIVES: 1. Describe recent developments in the medical management of advanced prostate ca...
Live from AUA2022: Highlights in Overactive Bladder
May 15, 2022 19:25 - 1 hour - 63.9 MBCME Available: https://auau.auanet.org/node/35599 Course Director: David A. Ginsberg, MD Faculty: Anne P. Cameron, MD, FRCSC, FPMRS; Sara M. Lenherr, MD, MS, FPRMS, Eric Rovner, MD; Eric Rovner, MD ACKNOWLEDGEMENTS This educational activity is supported by an independent educational grant from: Urovant LEARNING OBJECTIVES At the conclusion of the activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss...
Publishing Ethics
May 11, 2022 05:30 - 39.3 MBHost: Jay D. Raman, MD, FACS Guest: John P. Mulhall, MD Outline: Segment 1: The 4 R's of Scientific Publishing Segment 2: Plagiarism Segment 3: Authorship Issues Segment 4: Conflict of Interest Segment 5: IRB (IACUC)Issues Segment 6: Fabrication/Falsification Segment 7: Reviewer Malpractice Segment 8: Predatory Journals For more information, please visit: AUAnet.org/University
Publishing Ethics
May 11, 2022 05:30 - 42 minutes - 39.3 MBHost: Jay D. Raman, MD, FACS Guest: John P. Mulhall, MD Outline: Segment 1: The 4 R's of Scientific Publishing Segment 2: Plagiarism Segment 3: Authorship Issues Segment 4: Conflict of Interest Segment 5: IRB (IACUC)Issues Segment 6: Fabrication/Falsification Segment 7: Reviewer Malpractice Segment 8: Predatory Journals For more information, please visit: AUAnet.org/University
Adolescent and Young Adult (AYA) Oncology Focusing on Translocation RCC
May 04, 2022 05:30 - 34 minutes - 31.3 MBAdolescent and Young Adult (AYA) Oncology Focusing on Translocation RCC Co-Host: Nick G. Cost, MD Outline: Topic 1: Adolescents with cancer are different from both children and older adults with cancer Topic 2: Differences in biology Topic 3: Differences in clinical behavior Topic 4: Specific clinical trial options Topic 5: Summary – “Now what? What should I do the next time I see an AYA with kidney cancer?”
Global Advancements in Prostate Cancer: The Role of Genetic Testing and PARP Inhibitors
April 27, 2022 05:30 - 48 minutes - 44.2 MBCME Available: https://auau.auanet.org/node/35405 Moderator: Todd Morgan, MD Panelists: Maria Carlo, MD; Elisabeth Heath, MD, FACP; Brian Helfand, MD At the conclusion of this activity, participants will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients, explain how to counsel patients about genetic testing, and how to order and interpret these tests. 2. Explain how mutations in DNA damage repair genes can lead to the development of aggressive prost...
New Minimally Invasive BPH Treatment Options
April 20, 2022 11:24 - 34 minutes - 31.2 MBNew Minimally Invasive BPH Treatment Options Co-Host: John V. Kaspar, MD Acknowledgements: This podcast was funded by and developed in collaboration with Olympus Corporation. Outline: Segment 1: BPH patient needs Segment 2: AUA Guideline changes Segment 3: MIST procedures and patient selection Segment 4: Site of service for MIST treatment Segment 5: Anatomical considerations between therapies
Global Advancements in Prostate Cancer: Best Practices in Hormonal Therapy
April 13, 2022 05:30 - 47 minutes - 43.6 MBCME Available: https://auau.auanet.org/node/35401 Learning Objectives: After participating in this educational series, participants will be able to: 1. List advanced prostate cancer disease states (mHSPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urologic practice. 2. Identify available approved therapies and outcomes for each of these disease states: MHSPC, M0 CRPC, M1 CRPC. 3. Demonstrate the appropriate indications, unique mechanisms of action and side effects of new...
Conscious Sedation in the Urology Office
April 05, 2022 05:30 - 27.6 MBHost: Jay D. Raman, MD, FACS Guest: David B. Bock, MD, FACS Outline: Segment 1: Need for Office Sedation Segment 2: Types of procedures for which sedation can be utilized in the office Segment 3: Types of Anesthesia Segment 4: Office Readiness Segment 5: Implementation For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University
Update Series: Conscious Sedation in the Urology Office
April 05, 2022 05:30 - 30 minutes - 27.6 MBHost: Jay D. Raman, MD, FACS Guest: David B. Bock, MD, FACS Outline: Segment 1: Need for Office Sedation Segment 2: Types of procedures for which sedation can be utilized in the office Segment 3: Types of Anesthesia Segment 4: Office Readiness Segment 5: Implementation For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University
Prostate Biopsy: The Transperineal vs. Transrectal Debate
March 30, 2022 05:30 - 35 minutes - 32.3 MBHost: Jay D. Raman, MD, FACS Guest: Badar M. Mian, MD, FACS Outline: Segment 1: What are the main issues with transrectal biopsy? Segment 2: Proposed advantages of transperineal biopsy Segment 3: Some of the difference between the two techniques Segment 4: Ongoing RCTs Segment 5: Lessons learned during our RCT For more information, please visit: AUAnet.org/University
AUA2021 State-Of-The-Art Lecture First & Second Line Therapy In Advanced & Metastatic Bladder Cancer
March 23, 2022 05:30 - 16 minutes - 15 MBPresenter: Cora N. Sternberg, M.D.
AUA2021 State-Of-The-Art Lecture: Penile Fracture Causes And Management
March 16, 2022 18:27 - 13 minutes - 12.7 MBPresenter: Rafael E. Carrion, M.D.
AUA2021 Panel Discussion: The Future Of Urologic Oncology
March 09, 2022 06:30 - 35 minutes - 32.3 MBModerator: Samir S. Taneja, MD Panelists: Simpa Salami, MBBS, MPH Edouard Trabulsi, MD Brian Shuch, MD Cheryl T. Lee, MD
AUA2021 State-Of-The-Art Lecture: Robotic Ureteroscopy
March 02, 2022 06:30 - 15 minutes - 14.2 MBPresenter: Mitchell Humphreys, MD
AUA2021 Panel Discussion: Artificial Intelligence Applications In Urology
February 23, 2022 06:30 - 31 minutes - 29 MBModerator: Prokar Dasgupta, MD 3D Printing : Jamie Landman, MD Assessment of Surgical Competence: Andrew Hung, MD
AUA2021 State-Of-The-Art Lecture: Pain Management In FPMRS Surgery
February 16, 2022 06:30 - 18 minutes - 17.1 MBSpeaker: Nitya Abraham, MD
AUA2021 Panel Discussion: COVID And Sexual Medicine
February 09, 2022 06:30 - 22 minutes - 20.5 MBModerator: Nelson Bennett, MD Panel: Hypogonadism: Mohit Khera, MD Erectile Dysfunction: Alan Shindel, MD Telemedicine: Faysal Yafi, MD Infertility: Ranjith Ramasamy, MD
AUA2021 John Duckett Memorial Lecture: Nephron Sparing Surgery In The Management Of Wilms Tumor
February 02, 2022 06:30 - 26 minutes - 23.8 MBSpeaker: Thomas F. Kolon, MD
AUA2021 Journal Of Urology Lecture - The Promises And Pitfalls Of Large Database Studies
January 26, 2022 06:30 - 21 minutes - 20 MBSpeaker: David Penson, MD
AUA2021 Ramon Guiteras Lecture - Three Decades Of Bladder Cancer Treatment: Progress And Promise
January 19, 2022 06:30 - 20 minutes - 18.5 MBSpeaker: Eila C. Skinner, MD
AUA2021 John K. Lattimer Lecture - Kidney Stones: Is Prevention Possible?
January 12, 2022 06:30 - 20 minutes - 18.6 MBTitle: AUA2021 John K. Lattimer Lecture - Kidney Stones: Is Prevention Possible? Speaker: Glenn M. Preminger, MD Release: January 12
Testis Cancer – Apply the Guidelines to Clinical Practice
January 05, 2022 06:30 - 31 minutes - 29.2 MBHost: Jay Raman, MD, FACS Co-host: Scott Eggener, MD
How to Safely and Properly Administer Immunotherapies
December 29, 2021 06:30 - 33 minutes - 30.6 MBHow to Safely and Properly Administer Immunotherapies Podcast (2021) CME Available: https://auau.auanet.org/node/33496 ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Management of Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies
December 23, 2021 00:32 - 40 minutes - 37.3 MBManagement of Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies Podcast (2021) CME Available: auau.auanet.org/node/33488 ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Peer-Reviewed Guidance on How to Manage Immune-Related Adverse Events & Toxicities
December 15, 2021 15:05 - 43 minutes - 39.4 MBPeer-Reviewed Guidance on How to Manage Immune-Related Adverse Events & Toxicities Podcast (2021) CME Available: auau.auanet.org/node/33492 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Update
December 08, 2021 06:30 - 38 minutes - 35.4 MBAdvanced Prostate Cancer: AUA/ASTRO/SUO Guideline Update Podcast (2021) CME Available: auau.auanet.org/node/33467 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
How Can We Improve SDM A Prostate Cancer Survivor’s Perspective
December 01, 2021 06:30 - 34 minutes - 31.8 MBSupport provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc. CME Available: auau.auanet.org/node/31823 At the conclusion of this educational series, participants will be able to: 1. Discuss the impact of SDM on patients and on patient-clinician communication. 2. Identify at least one implementation strategy for using SDM in clinical practice....
Novel Imaging for High Risk Prostate Cancer
November 24, 2021 06:30 - 36 minutes - 33.1 MBNovel Imaging for High Risk Prostate Cancer Podcast (2021) CME Available: auau.auanet.org/node/33480 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Evolving Landscape of Androgen Deprivation Therapy in Advanced Prostate Cancer
November 17, 2021 06:30 - 35 minutes - 32.3 MBEvolving Landscape of Androgen Deprivation Therapy in Advanced Prostate Cancer Podcast (2021) CME Available: auau.auanet.org/node/33472 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Identification And Management Of Comorbid Conditions In The Patient With Advanced Prostate Cancer
November 10, 2021 06:30 - 36 minutes - 33.8 MBIdentification and Management of Comorbid Conditions in the Patient with Advanced Prostate Cancer Podcast (2021) CME Available: https://auau.auanet.org/node/33476 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Case Based Discussion: Role of Genetic Testing and End of Life Care
November 05, 2021 05:30 - 53 minutes - 49.2 MBRole of Genetic Testing in Advanced M1 CRPC & M1 CPRC Post-docetaxel, Neuroendocrine Cancer and End of Life Care Presented by Leonard Gomella, MD and Joshua Lang, MD https://auau.auanet.org/node/34071 Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme
Optimizing the Treatment of Complicated UTIs
November 03, 2021 05:30 - 35 minutes - 32.2 MBOptimizing the Treatment of Complicated UTIs CME Available: https://auau.auanet.org/node/33500 ACKNOWLEDGEMENT: This activity is supported by an independent educational grant from Spero Therapeutics.
Case Based Discussion: Early M1 CRPC & Advanced M1 CRPC
October 29, 2021 05:30 - 49 minutes - 44.9 MBEarly M1 CRPC & Advanced M1 CRPC Presented by Kelly Stratton, MD and Deborah Kaye, MD CME Available: https://auau.auanet.org/node/34065 Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme
Advances in Immuno-Oncology in Urothelial Carcinoma
October 27, 2021 19:19 - 36 minutes - 33.4 MBAdvances in Immuno-Oncology in Urothelial Carcinoma Podcast (2021) CME Available: https://auau.auanet.org/node/33484 This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Case Based Discussion: BCR and Novel Pet Imaging & M0 CRPC
October 22, 2021 05:30 - 46 minutes - 42.7 MBBCR and Novel Pet Imaging & M0 CRPC Presented by Stephen Boorjian, MD and Michael Cookson, MD CME Available: https://auau.auanet.org/node/34059 Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme
Refractory Overactive Bladder: How to Select 3rd Line Therapies and Optimize Outcomes
October 20, 2021 12:36 - 86.5 MBCME Available: https://auau.auanet.org/node/33881 At the conclusion of this course, participants will be able to: 1. Describe the various 3rd line therapies available to treat refractory OAB and will be able to discuss the pros and cons of each of the 3rd line therapies available to treat refractory OAB. 2. Explain with the current data regarding outcomes of PTNS, onabotulinumtoxinA, and sacral neuromodulation for treatment of refractory OAB. 3. Outline how to perform PTNS. Report how to per...
AUA Guidelines on Advanced/Metastatic/Castration Resistant Prostate Cancer
October 13, 2021 13:30 - 97.9 MBCME Available: https://auau.auanet.org/node/33900 At the conclusion of this course, participants will be able to: 1. Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC 2. Describe sequencing and indications for active treatment with approved agents in the management of nmCRPC 3. Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines 4. Improve diagnostic and therapeutic decision mak...